# US 2023/0233740 A1 · Osteoinductive bone regeneration material and production method of the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0233740 A1
- Document ID: US20230233740A1
- Status: Published application
- Kind: A1
- Application number: 18/002,608
- Filed: 2021-06-18
- Published: 2023-07-27
- Earliest claimed: 2020-06-21
- Assignees: Theradaptive, Inc.
- Applicants: Orthorebirth Co., Ltd.; Theradaptive, Inc.
- Inventors: Luis ALVAREZ; Yasutoshi NISHIKAWA; Hiroyuki TAIRA
- Web page: https://patentgrep.com/patent/US20230233740A1

## CPC

- A61L 27/46: with phosphorus-containing inorganic fillers
- A61L 27/56: Porous materials, {e.g. foams or sponges}
- A61L 27/58: Materials at least partially resorbable by the body
- D01D 1/02: Preparation of spinning solutions
- D01D 5/00: Formation of filaments, threads, or the like
- D01D 5/003: {the material being a polymer solution or dispersion (D01D5/0053 takes precedence)}
- D01F 6/92: of polyesters
- D02J 1/22: Stretching or tensioning, shrinking or relaxing, e.g. by use of overfeed and underfeed apparatus, or preventing stretch (stretch spinning D01D5/12)
- D02J 13/005: {by contact with at least one rotating roll}
- D06M 15/27: of alkylpolyalkylene glycol esters of unsaturated carboxylic acids
- D06M 16/00: Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
- A61L 2400/12: Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- D01F 1/10: Other agents for modifying properties
- D01F 6/84: from copolyesters
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- D01D: MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01F: CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D02J: FINISHING OR DRESSING OF FILAMENTS, YARNS, THREADS, CORDS, ROPES OR THE LIKE (curling or crimping D02G; by treatment with liquids, gases or vapours D06B; finishing other than by liquid treatment, of yarns in warp or sheet form D06C; for chemical matters, see D06L, D06M, D06P, D06Q; treatment during rope-making, apparatus for treating ropes auxiliary to rope-making D07B)
- D06M: TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS

## Abstract

A method of producing an osteoinductive bone graft formed of a plurality of electrospun biodegradable fibers is disclosed. The method includes preparing a fibrous scaffold material formed of the plurality of electrospun biodegradable fibers, wherein the plurality of electrospun biodegradable fibers are entangled with each other to form a cotton-wool like structure having inter-fiber spaces forming a microenvironment for cell growth therein, and immersing the fibrous scaffold in a solution containing BMP-2 so that the BMP-2 is bound to the calcium particles exposed on the surface of the fibers. Area of binding site for BMP-2 on calcium particles exposed on a surface of the electrospun biodegradable fibers is adjusted by an amount of the calcium particles contained in the electrospun biodegradable fibers.

## Claims

### Claim 1

A method of producing an osteoinductive bone regeneration material formed of a plurality of electrospun biodegradable fibers, comprising:
preparing a fibrous scaffold material formed of the plurality of electrospun biodegradable fibers, wherein the plurality of electrospun biodegradable fibers are 40-320 μm in diameter and 5-20 mm in length, wherein
the plurality of electrospun biodegradable fibers entangle with each other to form a cotton-wool like structure having inter-fiber spaces forming a microenvironment for cell growth therein,
the electrospun biodegradable fibers comprise 43-60 vol % β-TCP particles distributed in the electrospun biodegradable fibers such that a portion of the β-TCP particles is partially exposed on a surface of the electrospun biodegradable fibers without being coated by a polymer layer, and
immersing the fibrous scaffold in a solution containing BMP-2 so that the BMP-2 is bound to the β-TCP particles exposed on the surface of the fibers forming the microenvironment throughout the cotton-wool like structure to produce the osteoinductive bone graft, wherein an area of binding site for BMP-2 on β-TCP particles exposed on a surface of the electrospun biodegradable fibers is adjusted by an amount of the β-TCP particles contained in the electrospun biodegradable fibers.

### Claim 2 (depends on 1)

The method of claim 1, wherein diameters of the plurality of electrospun biodegradable fibers are 70-250 μm.

### Claim 3 (depends on 1)

The method of claim 1, wherein lengths of the plurality of electrospun biodegradable fibers are 4-10 mm.

### Claim 4 (depends on 1)

The method of claim 1, wherein the plurality of electrospun biodegradable fibers comprise PLGA.

### Claim 5 (depends on 1)

The method of claim 1, wherein diameters of the β-TCP particles are 2-5 μm.

### Claim 6 (depends on 1)

The method of claim 1, wherein the BMP-2 is targetable BMP-2.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

An osteoinductive bone regeneration material produced by the method of claims 1-6.

### Claim 8

A fibrous scaffold material for osteoinductive bone regeneration material comprising a plurality of electrospun biodegradable fibers, wherein the plurality of electrospun biodegradable fibers is 40-320 μm in diameter and 5-20 mm in length,
wherein the plurality of electrospun biodegradable fibers are entangled with each other to form a cotton-wool like structure having inter-fiber spaces forming a microenvironment for cell growth therein,
wherein the electrospun biodegradable fibers comprise 45-60 vol % 13-TCP particles distributed in the electrospun biodegradable fibers such that a portion of the β-TCP particles is partially exposed on a surface of the electrospun biodegradable fibers without being coated by a polymer layer,
wherein an area of binding site for BMP-2 on β-TCP particles exposed on a surface of the electrospun biodegradable fibers is adjusted by an amount of the β-TCP particles contained in the electrospun biodegradable fibers.

### Claim 9 (depends on 8)

The fibrous scaffold material of claim 8, wherein diameters of the plurality of electrospun biodegradable fiber are 70-250 μm.

### Claim 10 (depends on 8)

The fibrous scaffold material of claim 8, wherein lengths of the plurality of electrospun biodegradable fibers are 4-10 mm.

### Claim 11 (depends on 8)

The fibrous scaffold material of claim 8, wherein the electrospun biodegradable fibers comprise PLGA.

### Claim 12 (depends on 8)

The fibrous scaffold material of claim 8, wherein diameters of the β-TCP particles are 2-5 μm.

### Claim 13 (depends on 8)

The fibrous scaffold material of claim 8, wherein the β-TCP particles are bound to BMP-2.

### Claim 14 (depends on 13)

The fibrous scaffold material of claim 13, wherein the BMP-2 is targetable BMP-2.

### Claim 15

The fibrous scaffold material of any one of the previous claims, wherein the BMP-2 comprises any one of SEQ ID NOS: 1-38, or a combination or two more sequences from SEQ ID NOS: 1-38.

### Claim 16

A composition comprising:
a scaffold comprising about 60 wt % to about 80 wt % calcium containing compound, and
a targetable BMP-2 comprising (i) VIGESTHHRPWS (SEQ ID NO: 23, (ii) IIGESSHHKPFT (SEQ ID NO: 24), (iii) GLGDTTHHRPWG (SEQ ID NO: 25), (iv) ILAESTHHKPWT (SEQ ID NO: 26), or (v) a combination of two more of (i)-(iv).

### Claim 17 (depends on 16)

The composition of claim 16, wherein the targetable BMP-2 comprises VIGESTHHRPWS (SEQ ID NO: 23).

### Claim 18 (depends on 16, 17)

The composition of claim 16 or claim 17, wherein the targetable BMP-2 comprises IIGESSHHKPFT (SEQ ID NO: 24).

### Claim 19 (depends on 16, 17, 18)

The composition of any one of claims 16-18, wherein the targetable BMP-2 comprises GLGDTTHHRPWG (SEQ ID NO: 25).

### Claim 20 (depends on 16, 17, 18, 19)

The composition of any one of claims 16-19, wherein the targetable BMP-2 comprises ILAESTHHKPWT (SEQ ID NO: 26).

### Claim 21 (depends on 16, 17, 18, 19, 20)

The composition of any one of claims 16-20, wherein the targetable BMP-2 further comprises LLADTTHHRPWT (SEQ ID NO: 1).

### Claim 22 (depends on 16, 17, 18, 19, 20, 21)

The composition of any one of claims 16-21, wherein the targetable BMP-2 comprises QAKHKQRKRLKSSCKRHPLYVDFSDVGWND-WIVAPPGYHAFYCHGECPFPLADHLNSTNHAIVQTLVNSVNSKI PKACCVPTELSAISMLYLDENEKVVLKNYQDMVVEGCGCR (SEQ ID NO: 32).

### Claim 23 (depends on 16, 17, 18, 19, 20, 21, 22)

The composition of any one of claims 16-22, wherein the targetable BMP-2 comprises any one of SEQ ID NOS: 33-38.

### Claim 24 (depends on 16, 17, 18, 19, 20, 21, 22)

The composition of any one of claims 16-22, wherein the targetable BMP-2 comprises SEQ ID NO: 33.

### Claim 25 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 16-24, wherein the calcium containing compound comprises calcium phosphate, vaterite, or calcium phosphate and vaterite.

### Claim 26 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24)

The composition of any one of claims 16-24, wherein the calcium containing compound comprises beta-tricalcium phosphate (β-TCP).

### Claim 27 (depends on 26)

The composition of claim 26, wherein the β-TCP is present in the scaffold at about 60 wt % to about 80 wt % of the scaffold.

### Claim 28 (depends on 27)

The composition of claim 27, wherein the β-TCP is present in the scaffold at about 70 wt %.

### Claim 29 (depends on 26)

The composition of claim 26, wherein the β-TCP is present in the scaffold at about 30 wt % to about 50 wt % of the scaffold.

### Claim 30 (depends on 29)

The composition of claim 29, wherein the β-TCP is present in the scaffold at about 40 wt %.

### Claim 31 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 29, 30)

The composition of any one of claims 16-26 or claims 29-30, wherein the calcium containing compound comprises vaterite.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the vaterite is present in the scaffold at about 20 wt % to 40 wt % of the scaffold.

### Claim 33 (depends on 32)

The composition of claim 32, wherein the vaterite is present in the scaffold at about 30 wt %.

### Claim 34 (depends on 25, 31, 32, 33)

The composition of any one of claim 25 or 31-33, wherein the vaterite comprises silicon-doped vaterite (SiV).

### Claim 35 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The composition of any one of claims 16-34, wherein the scaffold comprises a biodegradable polymer.

### Claim 36 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The composition of any one of claims 16-34, wherein the scaffold comprises poly(lactic-co-glycolic acid) (PLGA).

### Claim 37 (depends on 36)

The composition of claim 36, wherein the scaffold comprises about 20 wt % to about 40 wt % PLGA.

### Claim 38 (depends on 37)

The composition of claim 37, wherein the scaffold comprises about 30 wt % PLGA.

### Claim 39

A method of treating a subject in need thereof, comprising admin-istering to the subject a composition of any previous claim.

### Claim 40 (depends on 38)

The method of claim 38, wherein the subject has a bone defect.
